ArticleFrontiers in immunology2026
A palmitoylation-associated three-gene signature predicts prognosis, immune features, and drug sensitivity in gastric cancer: functional validation of CTHRC1.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is a heterogeneous malignancy that requires improved molecular tools for prognostic stratification. Protein palmitoylation regulates membrane localization and signaling, but the clinical relevance of palmitoylation-related genes (PRGs) in GC remains unclear. Methods: Gene Expression Omnibus, The Cancer Genome Atlas, and GeneCards data were integrated to identify PRGs. Differential expression analysis, weighted gene co-expression network analysis, and three machine-learning algorithms were used to select key genes. Diagnostic and prognostic performance was evaluated in TCGA-STAD, platform-specific GEO cohorts, and an institutional cohort of 80 paired tissues. Immune infiltration, single-cell RNA sequencing, immunotherapy-related indices, and GDSC-based drug sensitivity were analyzed. CTHRC1 was further examined using clinical specimens, cell assays, and xenografts. Results: Thirteen differentially expressed PRGs were identified, and SERPINE1, CTHRC1, and EGR1 were selected. The integrated diagnostic model achieved AUCs of 0.935 in TCGA-STAD, 1.000 in GSE54129, and 0.916 in GSE118916, respectively. The three-gene score stratified overall survival in the total, training, and testing TCGA-STAD cohorts and in GSE84437, GSE236522, and the institutional cohort. It remained independently associated with survival in multivariable analysis. High-risk tumors showed increased stromal and immune scores, altered immune-cell composition, higher checkpoint expression, and higher TIDE scores. Single-cell analysis localized SERPINE1 and CTHRC1 mainly to fibroblast-related compartments. CTHRC1 knockdown reduced GC-cell proliferation, clonogenicity, migration, invasion, and xenograft growth while increasing apoptosis. Conclusion: The SERPINE1/CTHRC1/EGR1 signature provides prognostic and immune-stromal information in GC, and the experiments support a tumor-promoting role for CTHRC1. The findings define a palmitoylation-associated transcriptional framework but do not establish a palmitoylation-dependent mechanism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.